The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients.
Immunotherapy
; 11(17): 1481-1490, 2019 12.
Article
em En
| MEDLINE
| ID: mdl-31713453
ABSTRACT
Aim:
We performed a meta-analysis to explore the efficacy of immunotherapy for patients with squamous non-small-cell lung cancer (NSCLC). Materials &methods:
Randomized clinical trials comparing immunotherapy with chemotherapy for advanced NSCLC patients were included.Results:
A total of 11 trials (3112 patients) were included. PD-1/PD-L1 inhibitors demonstrated significant superiority to chemotherapy in overall survival (OS) (hazard ratio [HR] 0.74; p < 0.001) and progression-free survival (PFS) (HR 0.66; p < 0.001) for squamous NSCLC. The OS and PFS benefits of PD-1/PD-L1 inhibitors for squamous NSCLC were similar in subgroup analyses of line settings, PD-L1 expression and different study methodologies. No advantage in OS was found in advanced squamous NSCLC patients treated with atezolizumab (HR 0.87; p = 0.087).Conclusion:
PD-1/PD-L1 inhibitors significantly improved OS and PFS in advanced squamous NSCLC patients when compared with chemotherapy.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias de Células Escamosas
/
Carcinoma Pulmonar de Células não Pequenas
/
Antígeno B7-H1
/
Receptor de Morte Celular Programada 1
/
Neoplasias Pulmonares
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article